Eczema herpeticum Kaposi during treatment of a child with atopic dermatitis with 1% pimecrolimus cream;Wyprysk opryszczkowaty Kaposiego u dziecka z atopowym zapaleniem skóry w trakcie leczenia pimekrolimusem (1%, krem)

Postepy Dermatologii i Alergologii

Volumn 27, Issue 2, 2010, Pages 135-139

  Lesiak, Aleksandra ^a   Kopeć, Aleksandra ^b   Chruściel, Anna ^a   Sysa Jȩdrzejowska, Anna ^a   Narbutt, Joanna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Uniwersytetu Medycznego Łodzi ^*  (Poland)

Author keywords

Atopic dermatitis; Eczema herpeticum kaposi; Pimecrolimus

Indexed keywords

ACICLOVIR; PIMECROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CHILD; FACE; FEVER; HAND; HERPES SIMPLEX; HUMAN; LYMPHADENOPATHY; MALAISE; MALE; NECK; PRESCHOOL CHILD; SKIN DEFECT;

EID: 77952472130     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Leung DY, Nicklas RA, Li JT, et al. Disease menagement of atopic dermatitis: an updated practice parameter. Ann Allergy Astma Immunol 2004; 93 (3 suppl): S1-21.
2. Mohrenschlager M, Darsow U, Schnopp C, Ring J. Atopic eczema: what's new? J Eur Acad Dermatol Venereol 2006; 20: 503-511
3. Williams HC, Strachan DP, Hay RJ. Childhood eczema: disease of the advantaged. BMJ 1994; 308: 1132-1135
4. Turner JD, Schwarz RA. Atopic dermatitis. A clinical challenge. Acta Dermatovenerol Alp Panonica Adriat 2006; 15: 59-68.
5. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-876
6. Wüthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. J Investig Allergol Clin Immunol 2003; 13: 1-5. (Pubitemid 36781516)
7. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics 2008; 122: 812-824
8. Belloni B, Andres C, Ollert M, et al. Novel immunological approaches in the treatment of atopic eczema. Curr Opin Allergy Clin Immunol 2008; 8: 423-427
9. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK 506) leds to profund phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519-525 (Pubitemid 32210034)
10. Langley RG, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007; 215 (Suppl 1): 27-44.
11. Ingram JR, Martin JA, Finlay AY. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2009; 10: 229-237
12. Fabroni C, Lotti T. Pimecrolimus in dermatology. G Ital Dermatol Venereol 2009; 144: 321-325
13. Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006; 117: e118-28.
14. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Venereol (Stock) 1980; (Suppl 92): 44-47
15. Wahn U, Bos JD, Goodfield M, et al.; Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
16. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009; 123: 1124-1133
17. Kapp A, Papp K, Bingham A, et al.; Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-284
18. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515-525
19. Sehgal VN, Pahwa M. Pimecrolimus, yet another intriguing topical immunomodulator. J Dermatolog Treat 2007; 18: 147-150 (Pubitemid 46854830)
20. Büchau AS, Schauber J, Hultsch T, et al. Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol 2008; 128: 2646-2654
21. Narang T, Pahwa M, Kanwar AJ, Parsad D. Verruca vulgaris following treatment with tacrolimus ointment. Dermatology 2006; 213: 254-255 (Pubitemid 44567845)
22. Reitamo S. Rustin M, Harper J, et al.; 0.1% Tacrolimus Ointment Long-term Follow-up Study Group. A 4-year follow-up study in atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942-951
23. Kimata H. Kaposi's varicelliform eruption associated with the use of tacrolimus ointment in two neonates. Indian J Dermatol Venereol Leprol 2008; 74: 262-263 (Pubitemid 351918887)
24. Hwang YS, Spruance SL. The epidemiology of uncommon Herpes simplex virus type 1 infections. Herpes 1999; 6: 16-19 (Pubitemid 29335894)
25. Mackley CL, Adams DR, Anderson B, Miller JJ. Eczema herpeticum: a dermatologic emergency. Dermatol Nurs 2002; 14: 307-10, 323.
26. Shenoy MM, Suchitra U. Kaposi's varicelliform eruption. Indian J Dermatol Venereol Leprol 2007; 73: 65.
27. Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15: 169-178
28. Segura S, Romero D, Carrera C, et al. Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream. Acta Derm Venereol 2005; 85: 524-525
29. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999-1006.
30. Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol 2009; 124: 260-269
31. Bussmann C, Peng WM, Bieber T, Novak N. Molecular pathogenesis and clinical implications of eczema herpeticum. Expert Rev Mol Med 2008; 10: e21.